NCT07722286Completed
Relapse and Functional Outcomes in Anti-LGI1 Encephalitis
Relapse and Functional Outcomes in Anti-LGI1 Encephalitis: A Multicenter Study
Source: ClinicalTrials.gov · Last updated 23 Jul 2026
Brief summary (registry, in English)
This study focuses on a rare brain disease called anti-leucine-rich glioma-inactivated 1 (LGI1) encephalitis. In this condition, the body's immune system mistakenly attacks a protein in the brain, which can cause problems with memory, thinking, behavior, and seizures. While most patients get better with initial treatments, some continue to have long-term symptoms or experience a return of the disease (called a "relapse") months or years later. The goal of this study is to understand how often these relapses and long-term problems happen and to identify which patients are most at risk. The investigators will look back at the medical records of patients diagnosed with anti-LGI1 encephalitis at five major hospitals in Eastern China. The information about their symptoms, the treatments they received and how they recovered over time are obtained. Then, the investigators will analyze this information to find out what factors are linked to having a relapse or a poor long-term recovery. By understanding the risks for relapse and poor outcomes, doctors can better identify which patients need closer monitoring and more long-term treatment strategies. The results of this study will help create better guidelines for managing patients with this disease after their initial recovery, aiming to improve their quality of life in the long run.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 112 (actual)
- First submitted
- 29 Nov 2025
- Start date
- 1 Jan 2015
- Primary completion date
- 1 Jan 2026
- Lead sponsor
- Shen Chun-Hong
- NCT number
- NCT07722286
What you commit to
- Study type: Observational
- Participants enrolled: 112
- From 1 Jan 2015 to the primary completion date, 1 Jan 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- no prior use or lack of first-line immunotherapy
Other illness
- history of central nervous system (CNS) infections, severe neurological or primary psychiatric disorders
Other
- presence of coexisting neural autoantibodies
- insufficient follow-up data
Who the study is looking for
- Characteristic presentations of anti-LGI1 encephalitis;
- LGI1-immunoglobulin G (IgG) positivity in serum and/or cerebrospinal fluid (CSF) by fixed cell-based assay (Euroimmun, Lübeck, Germany)
- follow-up ≥ 18 months after initial immunotherapies
- exclusion of alternative diagnoses
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| 2nd Affiliated Hospital, School of Medicine, Zhejiang University, China Coordinator of this site? Confirm its status | Hangzhou | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.